Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director · 10% owner | April 01, 2016 | April 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date April 01, 2016 · Filed April 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.76 · Expires 2029-03-31 | Direct | 75,000 |
Reported balance
After 2019-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-01 · Grant · Acquired 75,000 · Balance 75,000 F1: 25% of the shares will become exercisable immediately and the remaining shares shall vest monthly thereafter over subsequent three years subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares will become exercisable immediately and the remaining shares shall vest monthly thereafter over subsequent three years subject to the Reporting Person's continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2019 Filed Apr 3, 2019 16:42 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001209191-19-023196 · doc4.xml · derivative · entry 1 During Matthew · CIK 0001704631 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-03-31 F1 · derivative.exercise_date: 25% of the shares will become exercisable immediately and the remaining shares shall vest monthly thereafter over subsequent three years subject to the Reporting Person's continued service through such date. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:42 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-013904 · doc4.xml · derivative · entry 1 During Matthew · CIK 0001704631 · Director · President and CSO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 16:39 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-18-004905 · doc4.xml · derivative · entry 1 During Matthew · CIK 0001704631 · Director · President and CSO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-01-18 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. Read SEC document |
| May 10, 2017 Filed May 10, 2017 17:14 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | ConversionSeries A Preferred Stock · Derivative | 28,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031374 · doc4.xml · derivative · entry 6 During Matthew · CIK 0001704631 · Director · President and CSO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date. Read SEC document |
| May 10, 2017 Filed May 10, 2017 17:14 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | ConversionCommon Stock | 28,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-031374 · doc4.xml · nonDerivative · entry 1 During Matthew · CIK 0001704631 · Director · President and CSO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,307,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.